nefopam-propacetamol combination
PreclinicalSmall molecule
nefopam-propacetamol combination is one of 7 small molecule programs targeting Postoperative Quality of Recovery. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
6 competitors in Postoperative Quality of Recovery
#DrugCompanyPhaseTrials
1Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Spravato
WWim Janssens
Approved
Dexmedetomidine-Esketamine
PPeking University First Hospital
Phase 3
Imitrex
GGlaxo Dba Glaxosmithkline
Preclinical
Ondexxya
UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
Preclinical
Ciprofol
Haisco Pharmaceutical Group Co., Ltd.Preclinical
nefopam-propacetamol combination
YYonsei University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- YYonsei University